Health & Veritas Katelyn Jetelina: A Visit from Your Local Epidemiologist
Howie and Harlan are joined by public health communicator Katelyn Jetelina for updates on COVID-19 and other issues, and to discuss how her emails to students and colleagues in the early days of the pandemic turned into a platform with global reach. Harlan looks at how AI is being used on both sides of the battle between providers and insurers over claims; Howie reports on a setback with a promising gene therapy for Duchenne muscular dystrophy.
Links:
Insurance Claims, AI, and Wearables
“Elevance Health Reports Second Quarter 2025 Results”
“Elevance lowers profit outlook, warns things will get worse for health insurers ““Blue KC wrongfully denied medical diagnoses, hospital alleges in AI-driven claims lawsuit”
“Oscar Health cuts full-year guidance, estimates 2025 loss as ACA marketplace stumbles”
“WHOOP Delivers Innovative Blood Pressure Insights for a Deeper Look at Your Well-Being”
“Introducing Heart Screener: A smarter way to stay connected to your heart health”
“Whoop says FDA is ‘overstepping its authority’ with warning about blood pressure feature”
FDA: WARNING LETTER, WHOOP, Inc.
“RFK Jr. wants everyone to use wearables. What are the benefits, risks?”
“Apple to Sell Watches With Blood-Oxygen Feature Disabled After Legal Setback”
Your Local Epidemiologist
“Poll: Trust in Public Health Agencies and Vaccines Falls Amid Republican Skepticism”
“Popular epidemiologist lays out future path of public health communication”
Yale School of Public Health: PopHIVE
Katelyn Jetelina: “NIH: The quiet engine of science is being dismantled”
Mayo Clinic: Norovirus infection
Katelyn Jetelina: “The show must go on...”
Katelyn Jetelina: “Harassment against scientists is out of control”
Katelyn Jetelina: “Medicaid cuts: The how and why”
CDC: H5 Bird Flu: Current Situation
CDC: Current Epidemic Trends (Based on Rt) for States”
CDC: Measles Cases and Outbreaks
Treating Duchenne Muscular Dystrophy
Cleveland Clinic: Duchenne Muscular Dystrophy (DMD)
“FDA approves Sarepta’s Duchenne gene therapy for nearly all patients”
“AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial”
“Patient dies in Sarepta gene therapy trial, adding to safety concerns”
“In surprise reversal, Sarepta Therapeutics says it will pause shipments of Duchenne gene therapy”
“Sarepta to lay off about 500 employees after Duchenne gene therapy setbacks”
Learn more about the MBA for Executives program at Yale SOM.